financetom
Business
financetom
/
Business
/
Sleep Number's Sales Decline Raises Market Share Loss Risk, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sleep Number's Sales Decline Raises Market Share Loss Risk, UBS Says
Mar 6, 2025 12:33 PM

03:04 PM EST, 03/06/2025 (MT Newswires) -- Sleep Number's ( SNBR ) Q4 sales declined as demand trends weakened and the company reduced media spending, raising concerns about market share risk, UBS Securities said in a note emailed on Thursday.

UBS expects a double-digit percentage sales decline in Q1, with major sales events already behind the company, making a near-term recovery unlikely.

The firm noted that Sleep Number ( SNBR ) cut media spending by 18% year-over-year in Q4, which helped profitability but raises questions about sustaining demand if spending remains low.

Despite weak unit sales, Sleep Number ( SNBR ) expanded gross margins by 330 basis points in Q4, aided by product mix and cost efficiencies, and some of these benefits could support profitability in the near term, UBS said.

Roughly one-third of Sleep Number's ( SNBR ) input materials come from Mexico, and potential tariffs could reduce margins by about 230 basis points if the company is unable to offset higher costs, UBS said. The firm noted that Sleep Number ( SNBR ) may seek to mitigate the impact through alternative sourcing, vendor negotiations, and selective price increases.

The firm also said that incoming CEO Linda Findley's background in digital businesses may help improve customer engagement and conversion. While the company remains committed to a direct-to-consumer model, UBS said the new leadership could explore strategic options, including potential partnerships.

The brokerage reduced the price target on Sleep Number's ( SNBR ) stock to $12 from $13 and maintained its neutral rating.

Shares of Sleep Number ( SNBR ) were down nearly 40% in recent trading.

Price: 7.78, Change: -5.11, Percent Change: -39.64

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Market Chatter: Trump, Xi Likely Needed to Revive Stalled US-China Trade Talks
Market Chatter: Trump, Xi Likely Needed to Revive Stalled US-China Trade Talks
May 30, 2025
08:04 AM EDT, 05/30/2025 (MT Newswires) -- Trade discussions with China have slowed and may require direct talks between President Donald Trump and Chinese President Xi Jinping, Fox News reported Thursday, citing an interview with US Treasury Secretary Scott Bessent. The breakthrough agreement two weeks ago paused tariff escalation for 90 days but left core trade issues unresolved, Bessent told...
Exclusive-Miner Vale misses deadline for power to expand Brazil nickel complex
Exclusive-Miner Vale misses deadline for power to expand Brazil nickel complex
May 30, 2025
SAO PAULO/RIO DE JANEIRO (Reuters) -Brazilian power grid operator ONS told Reuters it denied miner Vale's request to increase power consumption at its northern Onca Puma nickel complex, after missing a deadline to confirm the bid. The denial comes as Vale prepares to start up a second furnace at Onca Puma, a $555 million expansion that should help the miner...
Bioline Says Pilot Study of Potential Pancreatic Cancer Drug Combo Shows Improved Overall Response Rate; Shares Soar Pre-Bell
Bioline Says Pilot Study of Potential Pancreatic Cancer Drug Combo Shows Improved Overall Response Rate; Shares Soar Pre-Bell
May 30, 2025
08:00 AM EDT, 05/30/2025 (MT Newswires) -- Bioline RX ( BLRX ) said Friday that results from a pilot phase 2 clinical trial of its drug motixafortide, along with cemiplimab and standard-of-care chemotherapies, as a first-line treatment for pancreatic cancer showed that four out of 11 patients remained progression-free after more than one year. The study is evaluating the motixafortide...
Copyright 2023-2026 - www.financetom.com All Rights Reserved